Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
about
Gene Therapy for Cardiovascular DiseaseTo hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolasePhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionThe role of platelet-activating factor in mesangial pathophysiologyLipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipidsAtherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazoneNeointimal formation in two apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility.The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure.Phospholipase A(2) enzymes in metabolic and cardiovascular diseases.Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.Varespladib methyl in cardiovascular disease.Anti-oxidant properties of high-density lipoprotein and atherosclerosisEffect of alcohol on lipids and lipoproteins in relation to atherosclerosis.The emerging roles of PAF acetylhydrolase.Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).Post-intervention vessel remodeling.Mouse plasminogen has oxidized phosphatidylcholine adducts that are not metabolized by lipoprotein-associated phospholipase A₂under basal conditionsApplied gene therapy in preclinical models of vascular injury.Reductive metabolism increases the proinflammatory activity of aldehyde phospholipidsPlatelet-activating factor, a pleiotrophic mediator of physiological and pathological processes.Hepatic Overexpression of Soluble Urokinase Receptor (uPAR) Suppresses Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR-/-) Mice.Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system.Antithrombotic and antiatherosclerotic properties of olive oil and olive pomace polar extracts in rabbits.Oxidatively truncated phospholipids are required agents of tumor necrosis factor α (TNFα)-induced apoptosis.Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target.Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis.Aldose reductase-catalyzed reduction of aldehyde phospholipidsGene therapy of fibroproliferative vasculopathies: current ideas in molecular mechanisms and biomedical technology.Platelet-activating factor acetylhydrolase and transacetylase activities in human aorta and mammary arteryLipoprotein(a): a promising marker for residual cardiovascular risk assessment.New roles of HDL in inflammation and hematopoiesis.Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques.Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target.HDL and immunomodulation: an emerging role of HDL against atherosclerosis.Lp-PLA(2) as a marker of cardiovascular diseases.Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.
P2860
Q24791063-10A122E2-8E9C-428F-AFB5-1EA8C48B483FQ26865969-A6D8A0A4-11AF-48DF-AEEE-618464843D03Q26997377-34BE996E-AC7F-4E7F-97E6-EB9280A1A767Q28081511-132EFD56-7039-489F-B7D9-B93926645C5EQ28389004-81D4BF5A-1CBB-483D-8E9A-45D70D9DC71AQ28512042-7B88B1CF-92AF-4E0B-95C8-0425AEFF9713Q30434230-5B15A4BB-407E-47C2-B526-CCAC0AB8655CQ33566165-BC98A021-9DED-4706-8AE7-BF2971C30928Q33664201-9F291768-EC5B-43DC-8D8B-1825C7092E0EQ33773427-333DC1A3-871B-462B-A0E3-AB4C6FDB9F67Q33805731-80BA0D83-1EA5-465C-9901-F7DFD1CF5775Q34016317-DDEBE5E1-7FA9-4EE0-A622-93BA213A1F03Q34135420-FF3E2D8E-827B-436A-80C9-466440561DEBQ34440172-80905638-253F-4294-ACAB-AB80F7F585A3Q34743688-B6A3B99E-1BE3-488D-8002-A8097C79BEF0Q34847192-E4E9C324-6C58-4172-A12E-EAF8D69B31F0Q34864975-B15E8B5B-2354-4460-9D59-5CA3F135236CQ34983850-1211E4AE-6CB3-4739-BB25-5248B6D04E93Q35002146-E040304F-0E19-448E-B02D-C58F92F25CFEQ35095408-D7B471A8-B24E-4A85-9544-26EC7341D46EQ35561973-2EE36533-7CD6-4EFB-9D8D-7B6CD41A3668Q35621992-2C2E9237-3E2A-430E-8F25-F25F358F5B61Q35757527-7C055F75-6179-440D-A18C-AE43E82AC16AQ35839059-E26B9AFB-0F37-42B9-8504-2FCD0E71BEBAQ35925371-5B78F56A-51D5-41ED-B26B-5EA8D9BDFD50Q36006794-B45AADBE-8043-402B-B44A-14C83FAD51FBQ36145180-804A9FAE-3322-4E15-93D8-81CFCDE9783AQ36187055-52BE1251-F4C4-4B3B-B6C5-C773EEE2BB1EQ36269180-9B7D96C5-C977-4A1C-88BA-D0DF0C181042Q36304339-C58147EB-8C7A-4C5F-BF1B-B329627B666AQ36330024-4CE0F1CA-79C8-4FE8-B28E-263B9999C153Q36690251-52760F2D-3D0D-4EF6-9A82-8C9A83E22026Q36870588-3AA7E1EF-65E3-43D8-97BF-FBDF282CFB63Q37285933-B42D4296-484E-4899-AE0C-4C462086B94AQ37314961-DC90339B-7EA6-45F0-99D4-5ADA5A0D2A75Q37416056-3C38DE13-660A-48B8-A523-7534C63C3E2FQ37445865-1C850E67-2D38-407E-A55B-481B373EAB53Q37672264-FBE05055-BC4C-4448-8330-907FED24E906Q37738337-1A03C6CC-D60A-46A5-8EDC-2FF94AD32E31Q38079764-4AC87E99-0229-44F6-8B79-F2D9A1112D3A
P2860
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Adenovirus-mediated gene trans ...... olipoprotein E-deficient mice.
@ast
Adenovirus-mediated gene trans ...... olipoprotein E-deficient mice.
@en
type
label
Adenovirus-mediated gene trans ...... olipoprotein E-deficient mice.
@ast
Adenovirus-mediated gene trans ...... olipoprotein E-deficient mice.
@en
prefLabel
Adenovirus-mediated gene trans ...... olipoprotein E-deficient mice.
@ast
Adenovirus-mediated gene trans ...... olipoprotein E-deficient mice.
@en
P2093
P1433
P1476
Adenovirus-mediated gene trans ...... polipoprotein E-deficient mice
@en
P2093
B De Geest
C Michiels
G Theilmeier
P304
P356
10.1161/01.CIR.103.20.2495
P407
P577
2001-05-01T00:00:00Z